Akorn, Inc.

NASDAQ: AKRX
Akorn shares dipped on Tuesday after the firm announced that it received a warning letter from the FDA related to the inspection of its Somerset, New Jersey, manufacturing facility in July and August...
Akorn shares dipped on Wednesday after the company received a warning letter from the FDA regarding its Decatur, Illinois, manufacturing facility.
Bank of America, General Electric, Citigroup, and generic drugmaker Akorn posted new 52-week lows Friday.
Akorn, Snap, Lloyd's Bank, and Rite Aid all posted new 52-week lows Monday.
Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion merger deal.
Prothena, Akorn, Procter & Gamble, and Philip Morris all posted new 52-week lows Monday.
Fresenius said Sunday it would terminate its offer to acquire Akorn as the result of the latter's "failure to fulfill several closing conditions."
Celgene, Weatherford International, Akorn, and Cemex all posted new 52-week lows on Wednesday.
Fitbit, Akorn, Barrick Gold, and Cemex all posted new 52-week lows Tuesday.
Akorn saw its shares crater on Tuesday after some doubts were cast on its potential acquisition by German health care group Fresnius. This isn’t the first time that Akorn has faced concerns...
In this week's top stock picks from Jefferies, three very prominent biotechnology stocks are featured, including one that is a large cap leader.
Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full year.
March 18, 2016: Here are four stocks trading with heavy volume among 25 equities making new 52-week lows in Friday’s session. Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped...
24/7 Wall St. screened the RBC specialty pharmaceutical universe and found six companies rated Outperform with over 100% upside to the firm's price target.